BiOWiSH Technologies and SABIC Agri-Nutrients Company Announce Bio-Enhanced Mineral Fertilizer Collaboration

July 21, 2022 10:00 AM Eastern Daylight Time CINCINNATI–(BUSINESS WIRE)–BiOWiSH Technologies, Inc. and SABIC Agri-Nutrients Company (SABIC AN) announced the successful completion of a year-long technical evaluation of BiOWiSH® Crop Liquid technology coated on SABIC’s urea in nine countries across five continents … Continued

Knopp Biosciences and Population Health Partners Create Areteia Therapeutics, New Clinical-Stage Asthma Company, with $350 Million in Funding

PITTSBURGH, Pa. & SHORT HILLS, N.J.–(BUSINESS WIRE)–Jul 12, 2022– Areteia Therapeutics, Inc. (“Areteia”) today announces its launch as a clinical-stage biopharmaceutical company focused on putting asthma patients in better control of their disease – and back in control of their … Continued

Biohaven Acquires Kv7 Ion Channel Platform for the Treatment of Epilepsy and Other Neurologic Disorders From Channel Biosciences, a Subsidiary of Knopp Biosciences

– Acquisition of next-generation Kv7 channel activators for target indications including epilepsy, pain disorders and affective disorders – BHV-7000 is the lead asset from Kv7 channel platform and is potentially a best-in-class potassium channel activator with a profile suggestive for … Continued

Top Fintech Trends to Watch in 2022

NEW YORK, January 24, 2022 ( – Few industries have been as exciting and disruptive in recent years as the burgeoning fintech space. Between the evolution of digital payment methods and checkout options, and increased access to alternative investment opportunities for … Continued

Knopp Biosciences: Dexpramipexole targets eosinophilic inflammation

Knopp Biosciences’ investigational, first-in-class drug, dexpramipexole, holds promise for patients with asthma and eosinophil-associated diseases. Asthma affects more than 300 million people worldwide, and is the most common noncommunicable disease among children. No cure exists for chronic asthma; most patients … Continued

Yieldstreet Unveils High-End-Art Fund for Smaller Investors

Investment in YieldStreet’s art fund for smaller investors starts at $10,000 with returns aimed at 15% to 17%. Asset-investment firm Yieldstreet on Friday launched the Art Equity Platform, which is a series of funds that enable retail investors to buy into a … Continued